Triflusal

Base Information

• Chemical Name: Triflusal
• CAS No.: 322-79-2
• Molecular Formula: C10H7F3O4
• Molecular Weight: 248.158
• European Community (EC) Number: 206-297-5
• UNII: 1Z0YFI05OO
• DSSTox Substance ID: DTXSID8045305
• Nikkaji Number: J5.672C
• Wikipedia: Triflusal
• Wikidata: Q1758668
• NCI Thesaurus Code: C76407
• Metabolomics Workbench ID: 151926
• ChEMBL ID: CHEMBL1332032
• Mol file: 322-79-2.mol

Synonyms:2-acetoxy-4-trifluoromethylbenzoic acid;Disgren;triflusal

Chemical Property of Triflusal

Chemical Property:

• Vapor Pressure: 0.000178mmHg at 25°C
• Melting Point: 120-122° (upon slow heating); 110-112° (upon quick heating)
• Refractive Index: 1.483
• Boiling Point: 316 °C at 760 mmHg
• PKA: 2.97±0.10(Predicted)
• Flash Point: 144.9 °C
• Density: 1.433 g/cm³
• Storage Temp.: 2-8°C
• Solubility.: DMSO: >30mg/mL
• XLogP3: 2.1
• Hydrogen Bond Donor Count: 1
• Hydrogen Bond Acceptor Count: 7
• Rotatable Bond Count: 3
• Exact Mass: 248.02964319
• Heavy Atom Count: 17
• Complexity: 313

Purity/Quality:

99% ^*data from raw suppliers

Triflusal European Pharmacopoeia (EP) Reference Standard ^*data from reagent suppliers

Safty Information:

• Pictogram(s): Xn
• Hazard Codes: Xn
• Statements: 22-36/37/38-43
• Safety Statements: 26-36/37

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: CC(=O)OC1=C(C=CC(=C1)C(F)(F)F)C(=O)O
• Recent ClinicalTrials: ASpirin vs Triflusal for Event Reduction In Atherothrombosis Secondary Prevention (ASTERIAS)
• Recent EU Clinical Trials: Evaluación del tratamiento con triflusal en pacientes con cardiopatía isquémica estable con no respuesta a AAS
• Description: Triflusal is an antiplatelet agent structurally related to the salicylates, but it is not derived from ASA. Triflusal and its metabolite (3-hydroxy-4-triuoro-methylbenzoic acid or HTB) produce specic inhibition of platelet arachidonic acid metabolism (McNeely and Goa, 1998). A single 12-month open-label trial of Triflusal in 73 VaD patients (López-Pousa et al., 1997) showed fewer declines in MMSE scores in the active group compared with untreated subjects. More recently, Triflusal was used in patients with amnesic MCI; 257 patients were randomized to receive 900 mg of Triflusal or placebo for 18 months. Triflusal therapy was associated with a signicantly lower rate of conversion to dementia (Gómez-Isla et al., 2008).
• Uses: An analog of Aspirin; inhibits platelet aggregation. Antithrombotic. Antithrombotic;Cyclooxygenase inhibitor
• Clinical Use: Triflusal (2-acetoxy-4-trifluoromethyl benzoic acid) is an antiplatelet drug that despite its structural similarity to aspirin exhibits quite different pharmacological and pharmacokinetic properties.

Technology Process of Triflusal

There total 3 articles about Triflusal which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield:

3-Trifluoromethylphenol (98-17-9) → triflusal (322-79-2)

Guidance literature:

Multi-step reaction with 2 steps

1: K₂CO₃

With potassium carbonate;

DOI:10.1177/1077559501006004009

Reference yield:

4-trifluoromethylsalicylic acid (328-90-5) + acetic anhydride (108-24-7) → triflusal (322-79-2)

Guidance literature:

DOI:10.1177/1077559501006004009

Reference yield:

→ triflusal (322-79-2)

Guidance literature:

4-Trifluormethylsalicylsaeure, Ac2O, H2SO4;

upstream raw materials:

4-trifluoromethylsalicylic acid

acetic anhydride

3-Trifluoromethylphenol

Downstream raw materials:

acetic acid 2-chlorocarbonyl-5-trifluoromethylphenyl ester

acetate

4-trifluoromethylsalicylic acid